000504.SZ
南华生物
SZSE · Healthcare · M 科研服务 · CN
CNY 8.14
−3.44%Year over year
Reported trailing growth
- Revenue
- +291.7%
- EBITDA
- —
- EBIT
- +255.7%
- EPS
- +323.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +27.6%
- EBITDA
- +898.0%
- EBIT
- +196.3%
- Net income
- +245.3%
- EPS
- +250.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026